Nong Shaojun, Wei Zhongqing, Wang Zhiwei, Ma Limin, Guan Yangbo, Ni Jian
Department of Urological Surgery, The Affiliated Hospital of Nantong University, Nantong City, Jiangsu Province, China.
Department of Urological Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, China.
Stem Cells Dev. 2021 Sep 15;30(18):934-945. doi: 10.1089/scd.2021.0043. Epub 2021 Aug 17.
Prostate cancer (PCa) is a malignant tumor that originates in the male genitourinary system. Downregulation of death-associated protein kinase 1 (DAPK1) is closely related to PCa. Little is known about the functional role of DAPK1 in regulating cancer stem cell (CSC)-like characteristics of PCa cells, and we have conducted research on this topic. Compared with tumor-adjacent normal tissues, DAPK1 was severely downregulated in tumor tissues of PCa patients. DAPK1 expression was also reduced in PCa cell lines with respect to that in normal prostate cells. Moreover, we sorted PCa-CSCs (PCa-CD133 cells) from PCa cells. PCa-CD133 cells also exhibited a reduced DAPK1 level and elevated levels of stem cell markers (CD44, OCT4, and SOX2). DAPK1 knockdown promoted sphere formation and enhanced the proportions of PCa-CD133/PCa-CD133 cells. Inhibition of DAPK1 also accelerated migration and invasion of PCa-CD133 cells. In addition, DAPK1 interacted with zinc finger E-box-binding homeobox-1 (ZEB1) and repressed ZEB1 expression in PCa-CD133 cells. DAPK1 suppressed Hippo/YAP signaling pathway by interacting with ZEB1. Finally, we generated a tumor xenograft model to verify the effect of PCa-CD133 cells following DAPK1 overexpression on tumor growth of PCa. DAPK1 overexpression inhibited tumor growth of PCa and repressed the expression of ZEB1, YAP, and TAZ in the tumor tissues of PCa mice. In conclusion, reduced DAPK1 expression promoted stem cell-like characteristics of PCa cells through activating ZEB1 via Hippo/YAP signaling pathway. Taken together, this work sheds lights on the potential of DAPK1 as a target for PCa therapeutics from bench to clinic.
前列腺癌(PCa)是一种起源于男性泌尿生殖系统的恶性肿瘤。死亡相关蛋白激酶1(DAPK1)的下调与前列腺癌密切相关。关于DAPK1在调节前列腺癌细胞的癌症干细胞(CSC)样特性中的功能作用知之甚少,我们对此进行了研究。与癌旁正常组织相比,DAPK1在前列腺癌患者的肿瘤组织中严重下调。相对于正常前列腺细胞,前列腺癌细胞系中DAPK1的表达也降低。此外,我们从前列腺癌细胞中筛选出前列腺癌干细胞(PCa-CD133细胞)。PCa-CD133细胞也表现出DAPK1水平降低和干细胞标志物(CD44、OCT4和SOX2)水平升高。DAPK1基因敲低促进了球体形成并增加了PCa-CD133/PCa-CD133细胞的比例。抑制DAPK1也加速了PCa-CD133细胞的迁移和侵袭。此外,DAPK1与锌指E盒结合同源框-1(ZEB1)相互作用,并抑制PCa-CD133细胞中ZEB1的表达。DAPK1通过与ZEB1相互作用抑制Hippo/YAP信号通路。最后,我们建立了一个肿瘤异种移植模型,以验证DAPK1过表达后PCa-CD133细胞对前列腺癌肿瘤生长的影响。DAPK1过表达抑制了前列腺癌的肿瘤生长,并抑制了前列腺癌小鼠肿瘤组织中ZEB1、YAP和TAZ的表达。总之,DAPK1表达降低通过Hippo/YAP信号通路激活ZEB1,促进了前列腺癌细胞的干细胞样特性。综上所述,这项工作为DAPK1作为前列腺癌治疗靶点从实验室到临床的潜力提供了线索。